PharmTech Drug Digest 11.20
News|Videos|November 18, 2026

Transitioning mRNA from R&D to GMP

Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.

PharmTech spoke with Marco Pupo, PhD, innovation and development coordinator at Anemocyte, a biotech manufacturing organization that specializes in the contract development and manufacturing of plasmids, about what it takes to move mRNA from R&D to good manufacturing practice (GMP) production and what is needed for the facilities manufacturing these products. Anemocyte won the CPHI Award for Manufacturing Excellence at CPHI Milan 2026 in October for the company’s one-pot technology for messenger RNA (mRNA) synthesis, AMCAP.

As an example of the R&D to GMP transition, Pupo explains how AMCAP was developed in R&D but designed with GMP in mind from the outset. This approach was informed by Anemocyte’s more than 25 years of GMP manufacturing experience in biologics and advanced therapy products. Technologies built around research-grade enzymes formulated with BSA, glycerol, or other animal-derived components prove difficult to translate to GMP, so the team used GMP-grade, animal-free materials throughout development.

Pupo suggests that proprietary enzymes, plasmids, and NTPs be sourced from suppliers capable of providing regulatory starting materials along with the supporting documentation (eg, BSE/TSE statements) and validated analytical release testing. Companies should also adopt GMP-grade enzymes from the beginning rather than tolerating research-grade material early on; GMP enzymes are produced under stringent lot-to-lot activity assays and show less batch variability. Working with contract development and manufacturing companies that supply raw material is also important, because meeting sterile drug product expectations for endotoxin, bioburden, and elemental impurities depends on it.

On facility design, Pupo argues the pandemic-era mega-batch model is no longer the driver. Personalized vaccines targeting immuno-oncology indications and rare diseases require milligrams of mRNA rather than grams or kilograms, shifting the emphasis from scale-up to scale-down, and from large, fixed facilities to speed, modularity, and small footprint.

Turnaround speed matters clinically, and running 1 reaction instead of 2 or 3 shortens the process while maintaining segregation in closed systems, according to Pupo. Economic flexibility matters too: small batches carry high fixed costs, so minimizing consumption of cap analogs and enzymes is what makes personalized batches financially sustainable and, ultimately, deliverable to patients in time.


Related to this article